Casdin Capital Portfolio
Casdin Capital 13F filer (CIK 0001534261).
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q1 2016 · 26 positions · Total reported value $87.12M · Top-10 concentration 66.9% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 26.1% · 6 new · 3 cut · 3 exited
Active Share (vs S&P 500): 99.8% · vs QQQ: 99.9% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +47.2% · vs SPY +32.4% · Prev Value $1.32B — last quarter positions weighted by this quarter price moves · ranking
In its Q1 2016 13F filing, Casdin Capital disclosed 26 equity positions with a combined reported value of $87.12M. The filing implies a focused portfolio: its ten largest positions account for 66.9% of reported value. HoldingsHub classifies the profile as Small / Focused / High Turnover.
The largest disclosed positions as of Q1 2016 were LOXO ($6.83M), EPZM ($6.61M), FMI ($6.09M). By sector, the heaviest allocations are Health Care 32.2%, Other 67.8%.
Versus the prior quarter, Casdin Capital opened 6 new positions, trimmed 3 and fully exited 3, a turnover rate of 26.1% of positions. The portfolio's overlap with the prior quarter was 61% of names.
The largest new positions opened in Q1 2016 were EDIT ($2.95M), XBI ($2.58M), AVXS ($1.72M).
Of the 3 positions fully exited versus the prior quarter, the largest were ILMN ($3.84M), GNMK ($2.41M), NVTAQ ($2.05M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q1 2016)
- EDIT EDITAS MEDICINE INC · $2.95M
- XBI SPDR SERIES TRUST · $2.58M
- AVXS AVEXIS INC · $1.72M
- ONC BEONE MEDICINES LTD · $953.00K
- RXDX PROMETHEUS BIOSCIENCES INC · $745.00K
- EXAS EXACT SCIENCES CORP · $404.00K
Fully Exited (vs previous quarter)
- ILMN ILLUMINA INC · prev qtr: $3.84M · history
- GNMK GENMARK DIAGNOSTICS INC · prev qtr: $2.41M
- NVTAQ INVITAE CORP · prev qtr: $2.05M
- OSUR ORASURE TECHNOLOGIES INC · prev qtr: $1.09M
- JUNO JUNO THERAPEUTICS INC · prev qtr: $769.00K
- ATRA ATARA BIOTHERAPEUTICS INC · prev qtr: $660.00K
- TROV TROVAGENE INC · prev qtr: $378.00K
Insider Transactions (Form 4)
Latest Casdin Capital buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Casdin Capital is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 43 US equity positions with a combined value of $2.00B. HoldingsHub carries 43 quarters of its filings (Q4 2015–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-110894 (status: Approved), registered 2017-07-31
- Regulatory AUM (Form ADV): $2.87B as of 2026-03-31
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 5 private funds, of which 2 hedge funds
Portfolio Structure
- 43 positions · $2.00B reported value (Q2 2026)
- Top 10 holdings = 77.4% of reported value
- Largest position: RVMD (REVOLUTION MEDICINES INC) at 24.2%
- Average position size: $46.46M
Sector Tilt
- Health Care 94.2%
- Industrials 5.7%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 6 new, 9 added, 3 reduced, 3 exited
- 25 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
250.00K | $6.83M | 7.84% | Reduce | |
| 2 |
|
545.00K | $6.61M | 7.58% | Add | |
| 3 |
|
335.00K | $6.09M | 6.99% | Add | |
| 4 |
|
189.00K | $6.06M | 6.95% | Add | |
| 5 |
|
148.00K | $6.01M | 6.90% | Add | |
| 6 |
|
321.30K | $5.80M | 6.66% | Reduce | |
| 7 |
|
90.00K | $5.65M | 6.48% | Add | |
| 8 |
|
120.00K | $5.10M | 5.85% | Add | |
| 9 |
|
475.35K | $5.09M | 5.84% | Add | |
| 10 |
|
170.00K | $5.02M | 5.76% | Add | |
| 11 |
|
321.02K | $4.14M | 4.75% | Hold | |
| 12 |
|
75.00K | $3.44M | 3.95% | Add | |
| 13 |
|
339.36K | $2.96M | 3.40% | Add | |
| 14 |
|
85.47K | $2.95M | 3.39% | New | |
| 15 |
|
40.00K | $2.72M | 3.12% | Add | |
| 16 |
|
50.00K | $2.58M | 2.96% | New | |
| 17 |
|
63.00K | $1.72M | 1.97% | New | |
| 18 |
|
105.00K | $1.67M | 1.91% | Add | |
| 19 |
|
55.00K | $1.36M | 1.56% | Reduce | |
| 20 |
|
21.00K | $1.34M | 1.54% | Reduce | |
| 21 |
|
5.00K | $1.30M | 1.49% | Reduce | |
| 22 |
|
32.50K | $953.00K | 1.09% | New | |
| 23 |
|
110.00K | $745.00K | 0.85% | New | |
| 24 |
|
60.00K | $404.00K | 0.46% | New | |
| 25 |
|
10.00K | $387.00K | 0.44% | Hold | |
| 26 |
|
20.00K | $198.00K | 0.23% | Reduce | |
FAQ
What did Casdin Capital buy in 2016-Q1?
In its 2016-Q1 13F filing, Casdin Capital reported 26 equity positions worth $87.12M in aggregate; its largest disclosed positions were LOXO ($6.83M), EPZM ($6.61M), FMI ($6.09M).
How large is Casdin Capital's portfolio?
Casdin Capital reported $87.12M of long equity holdings across 26 positions as of 2016-Q1. Top-10 holdings account for 66.9% of reported value.
What is Casdin Capital's investment style?
HoldingsHub classifies the portfolio as Small / Focused / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.